FENC PE Ratio & Valuation,Is FENC Overvalued

FENC Relative Valuation

FENC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FENC is overvalued; if below, it's undervalued.

Historical Valuation

Fennec Pharmaceuticals Inc (FENC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.71 is considered Undervalued compared with the five-year average of 4.79. The fair price of Fennec Pharmaceuticals Inc (FENC) is between 11.55 to 12.88 according to relative valuation methord. Compared to the current price of 7.78 USD , Fennec Pharmaceuticals Inc is Undervalued By 32.7%.

Relative Value

Fair Zone

11.55-12.88

Current Price：7.78

32.7%

Undervalued

15.75

8.21

EV/EBITDA

Fennec Pharmaceuticals Inc. (FENC) has a current EV/EBITDA of 8.21. The 5-year average EV/EBITDA is 3.96. The thresholds are as follows: Strongly Undervalued below -21.37, Undervalued between -21.37 and -8.70, Fairly Valued between 16.62 and -8.70, Overvalued between 16.62 and 29.29, and Strongly Overvalued above 29.29. The current Forward EV/EBITDA of 8.21 falls within the Historic Trend Line -Fairly Valued range.

15.30

EV/EBIT

Fennec Pharmaceuticals Inc. (FENC) has a current EV/EBIT of 15.30. The 5-year average EV/EBIT is 17.24. The thresholds are as follows: Strongly Undervalued below -141.37, Undervalued between -141.37 and -62.07, Fairly Valued between 96.54 and -62.07, Overvalued between 96.54 and 175.84, and Strongly Overvalued above 175.84. The current Forward EV/EBIT of 15.30 falls within the Historic Trend Line -Fairly Valued range.

3.71

Fennec Pharmaceuticals Inc. (FENC) has a current PS of 3.71. The 5-year average PS is 16.85. The thresholds are as follows: Strongly Undervalued below -58.43, Undervalued between -58.43 and -20.79, Fairly Valued between 54.48 and -20.79, Overvalued between 54.48 and 92.12, and Strongly Overvalued above 92.12. The current Forward PS of 3.71 falls within the Historic Trend Line -Fairly Valued range.

7.01

P/OCF

Fennec Pharmaceuticals Inc. (FENC) has a current P/OCF of 7.01. The 5-year average P/OCF is -35.45. The thresholds are as follows: Strongly Undervalued below -373.90, Undervalued between -373.90 and -204.68, Fairly Valued between 133.78 and -204.68, Overvalued between 133.78 and 303.00, and Strongly Overvalued above 303.00. The current Forward P/OCF of 7.01 falls within the Historic Trend Line -Fairly Valued range.

7.01

P/FCF

Fennec Pharmaceuticals Inc. (FENC) has a current P/FCF of 7.01. The 5-year average P/FCF is -29.37. The thresholds are as follows: Strongly Undervalued below -365.37, Undervalued between -365.37 and -197.37, Fairly Valued between 138.63 and -197.37, Overvalued between 138.63 and 306.63, and Strongly Overvalued above 306.63. The current Forward P/FCF of 7.01 falls within the Historic Trend Line -Fairly Valued range.

Fennec Pharmaceuticals Inc (FENC) has a current Price-to-Book (P/B) ratio of -47.54. Compared to its 3-year average P/B ratio of -34.38 , the current P/B ratio is approximately 38.26% higher. Relative to its 5-year average P/B ratio of -13.30, the current P/B ratio is about 257.58% higher. Fennec Pharmaceuticals Inc (FENC) has a Forward Free Cash Flow (FCF) yield of approximately -3.10%. Compared to its 3-year average FCF yield of 0.35%, the current FCF yield is approximately -988.10% lower. Relative to its 5-year average FCF yield of -3.19% , the current FCF yield is about -3.00% lower.

-47.54

P/B

Median3y

-34.38

Median5y

-13.30

-3.10

FCF Yield

Median3y

0.35

Median5y

-3.19

Competitors Valuation Multiple

The average P/S ratio for FENC's competitors is 12.36, providing a benchmark for relative valuation. Fennec Pharmaceuticals Inc Corp (FENC) exhibits a P/S ratio of 3.71, which is -69.96% above the industry average. Given its robust revenue growth of 78.69%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of FENC increased by 19.46% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 6.97M to 12.46M.

The secondary factor is the P/E Change, contributed 34.54%to the performance.

Overall, the performance of FENC in the past 1 year is driven by Revenue Growth. Which is more sustainable.

78.69%

6.97M → 12.46M

Revenue Growth

-93.77%

-82.23 → -5.12

Margin Expansion

34.54%

-21.60 → -29.06

P/E Change

19.46%

6.32 → 7.55

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Fennec Pharmaceuticals Inc (FENC) currently overvalued or undervalued?

What is Fennec Pharmaceuticals Inc (FENC) fair value?

FENC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Fennec Pharmaceuticals Inc (FENC) is between 11.55 to 12.88 according to relative valuation methord.

How does FENC's valuation metrics compare to the industry average?

What is the current P/B ratio for Fennec Pharmaceuticals Inc (FENC) as of Dec 15 2025?

As of Dec 15 2025, Fennec Pharmaceuticals Inc (FENC) has a P/B ratio of -47.54. This indicates that the market values FENC at -47.54 times its book value.

What is the current FCF Yield for Fennec Pharmaceuticals Inc (FENC) as of Dec 15 2025?

As of Dec 15 2025, Fennec Pharmaceuticals Inc (FENC) has a FCF Yield of -3.10%. This means that for every dollar of Fennec Pharmaceuticals Inc’s market capitalization, the company generates -3.10 cents in free cash flow.

What is the current Forward P/E ratio for Fennec Pharmaceuticals Inc (FENC) as of Dec 15 2025?

As of Dec 15 2025, Fennec Pharmaceuticals Inc (FENC) has a Forward P/E ratio of 15.75. This means the market is willing to pay $15.75 for every dollar of Fennec Pharmaceuticals Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Fennec Pharmaceuticals Inc (FENC) as of Dec 15 2025?

As of Dec 15 2025, Fennec Pharmaceuticals Inc (FENC) has a Forward P/S ratio of 3.71. This means the market is valuing FENC at $3.71 for every dollar of expected revenue over the next 12 months.

FENC Valuation